Price to Earnings (P/E)
since 2005
Paying user area
Try for free
Cytokinetics Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cytokinetics Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Cytokinetics Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income (loss) allocable to common stockholders1 (in thousands) | ÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 1, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2021 | = | ÷ | = | ÷ | |||||||
| Mar 4, 2020 | = | ÷ | = | ÷ | |||||||
| Mar 7, 2019 | = | ÷ | = | ÷ | |||||||
| Mar 5, 2018 | = | ÷ | = | ÷ | |||||||
| Mar 6, 2017 | = | ÷ | = | ÷ | |||||||
| Mar 3, 2016 | = | ÷ | = | ÷ | |||||||
| Mar 6, 2015 | = | ÷ | = | ÷ | |||||||
| Mar 7, 2014 | = | ÷ | = | ÷ | |||||||
| Mar 15, 2013 | = | ÷ | = | ÷ | |||||||
| Mar 13, 2012 | = | ÷ | = | ÷ | |||||||
| Mar 11, 2011 | = | ÷ | = | ÷ | |||||||
| Mar 11, 2010 | = | ÷ | = | ÷ | |||||||
| Mar 12, 2009 | = | ÷ | = | ÷ | |||||||
| Mar 12, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 12, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 10, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Cytokinetics Inc. Annual Report.
Comparison to Competitors
Cytokinetics Inc., P/E, long-term trends, comparison to competitors
| Cytokinetics Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Moderna Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 1, 2023 | |||||||||||||
| Feb 25, 2022 | |||||||||||||
| Feb 26, 2021 | |||||||||||||
| Mar 4, 2020 | |||||||||||||
| Mar 7, 2019 | |||||||||||||
| Mar 5, 2018 | |||||||||||||
| Mar 6, 2017 | |||||||||||||
| Mar 3, 2016 | |||||||||||||
| Mar 6, 2015 | |||||||||||||
| Mar 7, 2014 | |||||||||||||
| Mar 15, 2013 | |||||||||||||
| Mar 13, 2012 | |||||||||||||
| Mar 11, 2011 | |||||||||||||
| Mar 11, 2010 | |||||||||||||
| Mar 12, 2009 | |||||||||||||
| Mar 12, 2008 | |||||||||||||
| Mar 12, 2007 | |||||||||||||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Cytokinetics Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Cytokinetics Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Mar 1, 2023 | ||
| Feb 25, 2022 | ||
| Feb 26, 2021 | ||
| Mar 4, 2020 | ||
| Mar 7, 2019 | ||
| Mar 5, 2018 | ||
| Mar 6, 2017 | ||
| Mar 3, 2016 | ||
| Mar 6, 2015 | ||
| Mar 7, 2014 | ||
| Mar 15, 2013 | ||
| Mar 13, 2012 | ||
| Mar 11, 2011 | ||
| Mar 11, 2010 | ||
| Mar 12, 2009 | ||
| Mar 12, 2008 | ||
| Mar 12, 2007 | ||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Cytokinetics Inc., P/E, long-term trends, comparison to industry (health care)
| Cytokinetics Inc. | Health Care | |
|---|---|---|
| Mar 1, 2023 | ||
| Feb 25, 2022 | ||
| Feb 26, 2021 | ||
| Mar 4, 2020 | ||
| Mar 7, 2019 | ||
| Mar 5, 2018 | ||
| Mar 6, 2017 | ||
| Mar 3, 2016 | ||
| Mar 6, 2015 | ||
| Mar 7, 2014 | ||
| Mar 15, 2013 | ||
| Mar 13, 2012 | ||
| Mar 11, 2011 | ||
| Mar 11, 2010 | ||
| Mar 12, 2009 | ||
| Mar 12, 2008 | ||
| Mar 12, 2007 | ||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).